checkmate 227 | Nivolumab plus Ipilimumab in Advanced Non

Keyword	CPC	PCC	Volume	Score	Length of keyword
checkmate 227	1.82	0.8	2632	45	13
checkmate	1.25	0.3	3887	86	9
227	1.26	0.9	6646	46	3

Keyword	CPC	PCC	Volume	Score
checkmate 227	0.1	0.4	7754	28
checkmate 227 trial	0.1	0.1	7716	45
checkmate 227 part 2	0.07	0.6	996	1
checkmate 227 update	1.51	0.5	3878	25
checkmate 227 tmb	1.11	0.7	3810	16
checkmate 227 5 year	1.89	0.8	9927	78
checkmate 227 6 years	1.95	0.7	1420	98
checkmate 227 pfs	0.14	0.2	1325	66
checkmate 227 nejm	0.25	0.5	1352	32
checkmate 227 part 1	1.24	0.8	3569	52
checkmate 227 jco	0.21	0.3	9076	62
checkmate 227 5years	1.4	0.2	4124	39
checkmate 227 regimen	0.18	0.6	6756	77
checkmate 227 squamous	0.07	0.7	3036	94
checkmate 227 4 year update	0.94	0.7	4749	29
checkmate 227 asco	1.36	0.8	1404	60
bms checkmate 227	1.95	0.5	7750	75

Search Results related to checkmate 227 on Search Engine

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1910231

WEBSep 28, 2019 · In CheckMate 227, a randomized, open-label, phase 3 trial, we evaluated nivolumab or nivolumab-based regimens as first-line treatment for advanced NSCLC. Part 1 of the trial has two independent...

DA: 49 PA: 100 MOZ Rank: 6

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.22.01503

WEBOct 12, 2022 · This long-term follow-up of CheckMate 227 revealed that patients who received nivolumab plus ipilimumab with tumor programmed death ligand 1 expression ≥ 1% or < 1% experienced 5-year overall survival rates of 24% and 19%, respectively.

DA: 23 PA: 2 MOZ Rank: 7

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1801946

WEBApr 16, 2018 · CheckMate 227 is an open-label phase 3 trial evaluating multiple hypotheses regarding the efficacy of nivolumab or nivolumab-based regimens as first-line treatment in biomarker-selected...

DA: 71 PA: 76 MOZ Rank: 48

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab
nih.gov

https://pubmed.ncbi.nlm.nih.gov/36223558/

WEBFeb 20, 2023 · Purpose: We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non-small-cell lung cancer, regardless of tumor programmed death ligand 1 …

DA: 53 PA: 47 MOZ Rank: 52

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4 …
nih.gov

https://pubmed.ncbi.nlm.nih.gov/34648948/

WEBIntroduction: In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive analysis). We report results with minimum 4 years' follow-up.

DA: 68 PA: 9 MOZ Rank: 78

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864530/

WEBFeb 12, 2022 · First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients - PMC. Journal List. ESMO Open. v.7 (1); 2022 Feb. PMC8864530. As a library, NLM provides access to scientific literature.

DA: 56 PA: 82 MOZ Rank: 73

Five-year survival outcomes with nivolumab (NIVO) plus …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2022.40.17_suppl.LBA9025

WEBJun 8, 2022 · Background: In CheckMate 227 part 1 (NCT02477826), 1L NIVO + IPI demonstrated long-term, durable survival benefit vs platinum-doublet chemo in patients (pts) with metastatic NSCLC regardless of tumor programmed death ligand 1 (PD-L1) expression level.

DA: 21 PA: 17 MOZ Rank: 8

CheckMate -227: Immunotherapy Combination Demonstrates Improved
mskcc.org

https://www.mskcc.org/news-releases/checkmate-227-immunotherapy-combination-demonstrates-improved-progression-free-survival-people-high-tumor-mutational-burden-advanced-non-small-cell-lung

WEBApr 16, 2018 · The combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) has shown improved progression-free survival (PFS) compared with chemotherapy as a first-line treatment for people with a high tumor mutational burden (TMB) in advanced non-small cell lung cancer (NSCLC).

DA: 56 PA: 60 MOZ Rank: 41

Bristol Myers Squibb - Six-Year Outcomes from Phase 3 CheckMate -227
bms.com

https://news.bms.com/news/details/2023/Six-Year-Outcomes-from-Phase-3-CheckMate--227-Trial-Show-Durable-Long-Term-Survival-with-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-in-the-First-Line-Treatment-of-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx

WEBSep 11, 2023 · CheckMate -227 is a multi-part open-label global randomized Phase 3 trial evaluating Opdivo -based regimens versus platinum-doublet chemotherapy in patients with first-line metastatic non-small cell lung cancer (NSCLC) across non-squamous and squamous tumor histologies.

DA: 6 PA: 59 MOZ Rank: 97

Landmark Five-Year Data from Phase 3 CheckMate -227 Trial …
bms.com

https://news.bms.com/news/details/2022/Landmark-Five-Year-Data-from-Phase-3-CheckMate--227-Trial-Demonstrate-Long-Term-Durable-Survival-Outcomes-with-Opdivonivolumab-Plus-Yervoy-ipilimumab-in-First-Line-Treatment-of-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx

WEBJun 6, 2022 · CheckMate -227 is a multi-part open-label global randomized Phase 3 trial evaluating Opdivo -based regimens versus platinum-doublet chemotherapy in patients with first-line metastatic non-small cell lung cancer (NSCLC) across non-squamous and squamous tumor histologies.

DA: 19 PA: 64 MOZ Rank: 20